Results 151 to 159 of about 2,146 (159)

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

European Journal of Neurology
Andreas Meisel, Masahisa Katsuno, Vera Bril   +2 more
exaly  

Ravulizumab auch gegen NMOSD wirksam

InFo Neurologie + Psychiatrie, 2023
openaire   +1 more source

PNH: Neue Daten zu Ravulizumab

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source

Meningococcal vaccines/Ravulizumab

Reactions Weekly
openaire   +1 more source

Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders

Multiple Sclerosis and Related Disorders
Tania Kümpfel, Edgar Meinl, Simone Mader   +2 more
exaly  

Hocheffektive Schubprophylaxe mit Ravulizumab

InFo Neurologie + Psychiatrie
openaire   +1 more source

An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder

Expert Opinion on Biological Therapy
Denis Balaban, Ray Borrow, Michael Levy   +2 more
exaly  

Post marketing real-world experience of ravulizumab in NMOSD

Multiple Sclerosis and Related Disorders
Luai Eldweik, Anu Jacob, Ahmed Shatila   +2 more
exaly  

Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis

Clinical Transplantation
exaly